Why GLP-1s Could Be an Anti-Aging Breakthrough 

For decades, researchers have searched for gerotherapeutic drugs—ones that slow the biological process of aging rather than target specific disease pathways—with little progress. But in recent years, GLP-1 drugs like Ozempic and Wegovy have started to make researchers rethink what an anti-aging drug might look like.

These drugs were developed to lower blood sugar, but their benefits appear to extend well beyond diabetes and weight loss. Studies have linked GLP-1s to improvements in cardiovascular and kidney disease, and early research suggests they may also affect mild cognitive impairment, chronic inflammation, immune function, and some measures of epigenetic aging.

As the list of potential benefits has grown, it has caught geroscientists’ attention. They are now investigating whether these drugs treat several age-related conditions separately—or act on something those conditions share.

A new study in Nature has added to that possibility. Researchers found that semaglutide—the active ingredient in Ozempic and Wegovy—slowed several signs of aging and extended lifespan in healthy older mice. The results do not demonstrate that GLP-1 drugs slow aging in people. But the findings have made one question more urgent: Could GLP-1 drugs do more than treat age-related diseases—and actually slow aging?

Why GLP-1 Drugs Have Longevity Researchers Excited

Part of what has captured researchers’ attention is that GLP-1 drugs appear to benefit several organ systems at once. Beyond their effects on blood sugar and body weight, studies have found benefits for cardiovascular and kidney health. They also seem especially beneficial for people with high inflammation.

“In people living with HIV, diabetes-drug interventions like semaglutide have shown reductions in some biological-age measures,” says Raghav Sehgal, an associate research scientist on human aging at Yale School of Medicine. “So these drugs may be most useful where metabolic and inflammatory burden is already high.”

GLP-1s are not the only diabetes drugs showing benefits across several age-related conditions. SGLT2 inhibitors, another class of medications developed to lower blood sugar, have been shown to improve cardiac function and protect against heart failure by activating a key enzyme that improves the heart’s efficiency and contractile function. They can also slow chronic kidney disease (CKD) progression in patients with related conditions like diabetes, obesity, or heart failure, although the evidence to support their use in lean, non-diabetic CKD patients is less clear. 

(Are We on the Brink of Ending Aging?)

Animal studies have gone a step further. In the Nature study described earlier, researchers treated healthy 20-month-old female mice with semaglutide. After three months, the mice performed better on tests of memory, motor function, muscle strength, and glucose control. They also showed improvements in several hallmarks of aging, including chronic inflammation, cellular senescence, mitochondrial function, and stem cell decline. In a separate group that continued receiving semaglutide, median lifespan increased from 742 to 834 days—about 12 percent.

Matt Kaeberlein, a biogerontologist whose work focuses on the biological mechanisms of aging, says these findings are impressive. Still, they don’t yet prove beyond a doubt that these drugs are slowing aging. They’re just consistent with what you’d expect of a drug that slows aging because they impact multiple age-related diseases.

What Animal Studies Can—and Can’t—Tell Us

So far, increased lifespan has only been demonstrated in rodents. Experts are divided on how accurately animal studies can translate to human aging. Still, Kaeberlein says that mice and rats are among the most useful laboratory models for studying aging across an entire lifespan. He believes longevity scientists can develop “really good evidence bases to support that idea that it affects aging biology,” even without waiting for a human lifespan study.

Proving that a drug actually extends lifespan in humans is far more difficult, since a definitive study could take decades. For now, evidence that these drugs actually slow aging in people is “going to be much more speculative,” he adds.

Sehgal, the author of a 2026 study in Nature Medicine, is also skeptical. The researchers looked at biological age and aging biomarkers across 51 longevity interventions, including lifestyle changes, supplements, and medications such as semaglutide. Although medications as a group were associated with reductions in biological age, semaglutide did not have that effect in the healthy older adults included in the analysis, he says. “It is clearly a valuable drug for obesity and diabetes, but losing weight or improving glucose control is not the same as showing that aging itself has slowed.”

How These Drugs May Impact Aging

One possible reason GLP-1 drugs benefit so many age-related conditions is that they suppress appetite, causing people to eat fewer calories. “If you look in the literature—at least in laboratory animals—caloric restriction is by far the gold standard for ways to slow aging and increase lifespan,” says Kaeberlein. A 2026 study in Clinical Nutrition found that two years of calorie restriction slowed increases in biological-age measures across several organ systems, with the strongest effects in the metabolic and cardiovascular systems.

One of the big questions, though, is whether GLP-1 drugs are actually affecting aging or whether patients are simply getting healthier because of weight loss, says Mia Lussier, a clinical assistant professor at Binghamton University.

(The Unexpected Ways Ozempic-Like Drugs Might Fight Dementia.)

The new mouse study tried to separate these effects by comparing semaglutide with an equivalent calorie reduction. The two groups of mice ate similar amounts of food and lost similar amounts of weight. Both interventions helped preserve physical function as the mice aged, but semaglutide produced greater improvements in spatial memory, exploratory behavior, and glucose control.

That suggests at least some of its effects may extend beyond eating less. However, the lifespan portion of the study compared semaglutide-treated mice with untreated mice—not with a calorie-restricted group—so it could not show whether the longer lifespan was independent of reduced calorie intake.

One explanation is that the drugs may affect what researchers call the hallmarks of aging, biological changes associated with cellular decline and age-related diseases, including chronic inflammation, epigenetic alterations,  and mitochondrial dysfunction. “They are things that go wrong when you’re old, and when you fix them, the whole body improves,” says Nir Barzilai, director of the Institute for Geroscience at the Albert Einstein College of Medicine. “If it’s in animals, they live longer.”

Barzilai says this is what sets potential gerotherapeutics apart from drugs that prevent a single age-related disease. Take cholesterol-lowering statins, for example. They can reduce the risk of cardiovascular disease without necessarily affecting the broader processes associated with aging. A true gerotherapeutic would be expected to act on several of those processes and reduce the risk of multiple age-related diseases.

However, researchers are still unclear about how these hallmarks work together, and which—if any—are the most important. Barzilai, who also serves as the president of the Academy of Geroscience, oversees a team of scientists working to understand these hallmarks. “They all like to say their hallmark is in the middle,” he says. “But the hallmarks of aging are not telling you which is the primary mechanism of aging. We don’t know the whole truth yet.”

What Does the Future of Anti-Aging Drugs Look Like?

That uncertainty is also shaping how researchers think about the potential use of these drugs in older adults. Neither GLP-1 drugs nor SGLT2 inhibitors are approved to slow aging, and no evidence shows that healthy people should take them for that purpose.

Still, doctors can prescribe the drugs off-label, but experts differ on when that might make sense for disease prevention or healthy aging. Kaeberlein says he would feel comfortable recommending these drugs off-label in certain circumstances, while Lussier says she won’t consider GLP-1s for non-diabetic patients unless they have a BMI over 27.

Although these drugs have been studied for years in people with diabetes or obesity, much less is known about the effects of taking them for decades—particularly among otherwise healthy people. “We don't know what the consequence at a population level of millions of people taking these drugs for decades is going to be,” Kaeberlein says. “We just have to recognize there are uncertainties here.”

(Ozempic and Mounjaro Have Another Benefit: Treating Inflammation.)

GLP-1 drugs can cause loss of lean mass alongside significant weight loss, which may be especially concerning for older adults, says Lussier. Researchers are still determining how much of that loss represents muscle and whether these drugs affect bone density. “If you fall and break a hip, the outcomes are already poor to begin with,” she says. What happens when you compound that risk by losing muscle and bone mass? She is also hesitant to use them in older adults because appetite suppression can make it harder to consume enough protein and other nutrients.

To combat these risks, some researchers are studying whether lower, or “micro,” doses might produce fewer side effects. Others are investigating medications that could be used alongside GLP-1 drugs to preserve muscle mass.

For Kaeberlein, the next question that researchers need to tackle is: Can we find a dose or a protocol where the benefits greatly outweigh the potential risks? “I think that’s possible,” he says.